The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI

Yıl: 2016 Cilt: 46 Sayı: 3 Sayfa Aralığı: 604 - 613 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI

Öz:
Background/aim: The thrombolysis in myocardial infarction (TIMI) risk score (TRS), and the TIMI risk index (TRI) have been reported in coronary artery disease patients. We investigated whether admission TRI is associated with no-reflow (NRF) in patients undergoing primary percutaneous coronary intervention (p-PCI). Materials and methods: ST-segment elevation myocardial infarction (STEMI) patients treated with p-PCI were included in the study. TRI was calculated on admission using specified variables. We defined the angiographic NRF phenomenon as a coronary TIMI flow grade of &#8804;2 after the vessel was recanalized or a TIMI flow grade of 3 together with a final myocardial blush grade (MBG) of <2 in a manner as described in previous studies. Results: A total of 371 patients (aged 62 ± 14 years; 73/27 men to women ratio) who underwent p-PCI were enrolled in the study. In terms of age, NRF patients were older than reflow patients (P < 0.017 for MBG). Killip class III-IV designations were more common in NRF patients (P = 0.029 for MBG). TRI (P = 0.014 for MBG) values were significantly greater in the NRF group. TRI was an independent predictor of NRF according to MBG flow (P = 0.003, B = 0.035, Exp B = 0966, 95% CI, 0.944 0.988). Conclusion: Admission TRI may predict the development of NRF phenomenon after p-PCI in patients with acute STEMI.
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Santos ES, Aguiar Filho Lde F, Fonseca DM, Londero HJ, Xavier RM, Pereira MP, Minuzzo L, Souza Rd, Timerman A. Correlation of risk scores with coronary anatomy in non-STelevation acute coronary syndrome. Arq Bras Cardiol 2013; 100: 511-517.
  • 2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, BlömstromLundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
  • 3. Harrison RW, Aggarwal A, Ou FS, Klein LW, Rumsfeld JS, Roe MT, Wang TY; . Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol 2013; 111: 178-184.
  • 4. Magro M, Nauta ST, Simsek C, Boersma E, van der Heide E, Regar E, van Domburg RT, Zijlstra F, Serruys PW, van Geuns RJ. Usefulness of the SYNTAX score to predict ‘‘no reflow’’ in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol 2012; 109: 601-606.
  • 5. Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, Pache J, Alger P, Mehilli J, Schömig A et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 2010; 55: 2383-2389.
  • 6. Akpek M, Kaya MG, Lam YY, Sahin O, Elcik D, Celik T, Ergin A, Gibson CM. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2012; 110: 621- 627.
  • 7. Celik T, Kaya MG, Akpek M, Yarlioglues M, Sarli B, Topsakal R, Gibson CM. Does serum bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI. Angiology 2014; 65: 198-204.
  • 8. Sen N, Afsar B, Ozcan F, Buyukkaya E, Isleyen A, Akcay AB, Yuzgecer H, Kurt M, Karakas MF, Basar N et al. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with STelevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis 2013; 228: 203-210.
  • 9. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardio Inte 2008; 72: 950-957.
  • 10. Yildiz A, Yuksel M, Oylumlu M Polat N, Akyuz A, Acet H, Aydin M, Ülgen MS. The utility of the platelet-lymphocyte ratio for predicting no reflow in patients with ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost 2015; 21: 223-228.
  • 11. Braunwald E, Antman EM, Beasley JW Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) J Am Coll Cardiol 2002; 40: 1366-1374.
  • 12. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUITS Investigators. Circulation 2000; 101: 2557-2567.
  • 13. de Araújo Gonçalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005; 26: 865-872.
  • 14. Granger CB, Goldberg RJ, Dabbous O Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345- 2353.
  • 15. Wiviott SD, Morrow DA, Frederick PD, Giugliano RP, Gibson CM, Mc Cabe CH, Cannon CP, Antman EM, Braunwald E. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and-4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44: 783-789.
  • 16. Bradshaw PJ, Ko DT, Newman AM, Donovan LR, Tu JV. Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk index for predicting early mortality in a population-based cohort of STEMI and non-STEMI patients. Can J Cardiol 2007; 23: 51-56.
  • 17. Garcia S, Canoniero M, Peter A, de Marchena E, Ferreira A. Correlation of TIMI risk score with angiographic severity and extent of coronary artery disease in patients with non-STelevation acute coronary syndromes. Am J Cardiol 2004; 93: 813-816.
  • 18. Acet H, Ertaş F, Bilik MZ, Akıl MA, Özyurtlu F, Aydın M, Oylumlu M, Polat N, Yuksel M, Yıldız A et al. The relationship between neutrophil to lymphocyte ratio, platelet to lymphocyte ratio and TIMI risk score in patients with STEMI before primary coronary intervention. Postepy Kardiol Interwencyjnej 2015; 11: 126-135.
  • 19. Acet H, Ertaş F, Akıl MA, Ozyurtlu F, Polat N, Bilik MZ, Aydın M, Oylumlu M, Yüksel M, Yıldız A et al. Relationship between hematologic indices and global registry of acute coronary events risk score in patients with ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost 2016; 22: 60-68.
  • 20. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-1513.
  • 21. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-464.
  • 22. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102: 2031-2037.
  • 23. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI study group. New Engl J Med 1985; 312: 932e6.
  • 24. Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, Garcia E, Tcheng JE, Mehran R, Lansky AJ et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 2005; 26: 667-674.
  • 25. Gibson CM, Murphy SA, Morrow DA, Aroesty JM, Gibbons RJ, Gourlay SG, Barron HV, Giugliano RP, Antman EM, Braunwald E. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am Heart J 2004; 148: 336e40.
  • 26. Kristensen SD, Fajadet J, Di Mario C, Kaifoszova Z, Laut KG, Deleanu D, Gilard M, Guagliumi G, Goktekin O, Jorgova J et al. Implementation of primary angioplasty in Europe: stent for life initiative progress report. EuroIntervention 2012; 8: 35-42.
  • 27. Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, Andrikopoulos G, Baz JA, Betriu A, Claeys M et al. Reperfusion therapy for ST-elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 2010; 31: 943-957.
  • 28. Laut KG, Pedersen AB, Lash TL, Kristensen SD. Barriers to implementation of primary percutaneous coronary intervention in Europe. European Cardiology 2011; 7: 108-112.
  • 29. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O’Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The primary angioplasty in myocardial infarction study group. New Engl J Med 1993; 328: 673-679.
  • 30. Reffelmann T, Kloner RA. The no-reflow phenomenon: basic science and clinical correlates. Heart 2002; 87: 162-168. 31. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Card 2006; 3: 499- 506.
  • 32. Pan W, Liu HW, Wang LF, Li ZQ, Sun XY. Effect of percutaneous thrombectomy on echocardiographic measures of myocardial microcirculation in elderly patients with acute myocardial infarction. Coronary Artery Dis 2010; 21: 121-125.
  • 33. Huczek Z, Kochman J, Filipiak KJ, Horszczaruk GJ, Grabowski M, Piatkowski R, Wilczynska J, Zielinski A, Meier B, Opolski G. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 46: 284-290.
  • 34. Galasso G, Schiekofer S, D’Anna C, Gioia GD, Piccolo R, Niglio T, Rosa RD, Strisciuglio T, Trimarco B. No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. Angiology 2014; 65: 180-189.
  • 35. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-292.
  • 36. Botto N, Sbrana S, Trianni G, Andreassi MG, Ravani M, Rizza A, Al-Jabri A, Palmieri C, Berti S. An increased plateletleukocytes interaction at the culprit site of coronary artery occlusion in acute myocardial infarction: a pathogenic role for ‘‘no-reflow’’ phenomenon? Int J Cardiol 2007; 117: 123-130.
  • 37. Maseri A, Rebuzzi AG, Cianflone D. Need for a composite risk stratification of patients with unstable coronary syndromes tailored to clinical practice. Circulation 1997; 96: 4141-4142.
  • 38. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-322.
  • 39. Becker RC, Burns M, Gore JM, Spencer FA, Ball SP, French W, Lambrew C, Bowlby L, Hilbe J, Rogers WJ. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice: the National Registry of Myocardial Infarction (NRMI-2) Participants. Am Heart J 1998; 135: 786-796.
  • 40. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock: SHOCK Investigators: should we emergently revascularize occluded coronaries for cardiogenic shock. New Engl J Med 1999; 341: 625-634.
  • 41. Tang EW, Wong CK, Herbison P. Global registry of acute coronary events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J 2007; 153: 29-35.
  • 42. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA Giugliano RP, McCabe CH, Braunwald E. TIMI risk score for ST-elevation myocardial infarction, a convenient, bedside, clinical score for risk assessment at presentation: an intravenous Npa for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102: 2031-2037.
  • 43. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
  • 44. Morrow DA, Antman EM, Person L, de Lemos JA, Cannon CP, Giugliano RP, McCabe CH, Barron HV, Braunwald E. Application of TIMI risk score for ST elevation myocardial infarction in the National Registry of Myocardial Infarction 3. JAMA 2001; 286: 1356-9135.
  • 45. Mega JL, Morrow DA, Sabatine MS, Zhao XQ, Snapinn SM, Di Battiste PM, Gibson CM, Antman EM, Braunwald E, Théroux P. Correlation between the TIMI risk score and high-risk angiographic findings in non-ST- elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Am Heart J 2005; 149: 846-850.
  • 46. InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-2013.
  • 47. Morrow DA, Antman EM, Giugliano RP, Cairns R, Charlesworth A, Murphy SA, de Lemos JA, McCabe CH, Braunwald E. A simple risk index for rapid initial triage of patients with STelevation myocardial infarction: an InTIME II substudy. Lancet 2001; 358: 1571-1575.
  • 48. Rathore SS, Weinfurt KP, Gross GP, Krumholz HM. Validity of a simple ST-elevation acute myocardial infarction risk index: are randomized trial prognostic estimates generalizable to elderly patients? Circulation 2003; 107: 811-816.
APA ACET H, ERTAŞ F, AKIL M, BILIK M, AYDIN M, POLAT N, YILDIZ A, Yüksel M, ÇİFTÇİ L, ÖZAYDOĞDU N, özbek m, alan s, TOPRAK N (2016). The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI. , 604 - 613.
Chicago ACET Halit,ERTAŞ Faruk,AKIL Mehmet Ata,BILIK MEHMET ZIHNI,AYDIN MESUT,POLAT Nihat,YILDIZ Abdulkadir,Yüksel Murat,ÇİFTÇİ Leyla,ÖZAYDOĞDU Necdet,özbek mehmet,alan sait,TOPRAK Nizamettin The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI. (2016): 604 - 613.
MLA ACET Halit,ERTAŞ Faruk,AKIL Mehmet Ata,BILIK MEHMET ZIHNI,AYDIN MESUT,POLAT Nihat,YILDIZ Abdulkadir,Yüksel Murat,ÇİFTÇİ Leyla,ÖZAYDOĞDU Necdet,özbek mehmet,alan sait,TOPRAK Nizamettin The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI. , 2016, ss.604 - 613.
AMA ACET H,ERTAŞ F,AKIL M,BILIK M,AYDIN M,POLAT N,YILDIZ A,Yüksel M,ÇİFTÇİ L,ÖZAYDOĞDU N,özbek m,alan s,TOPRAK N The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI. . 2016; 604 - 613.
Vancouver ACET H,ERTAŞ F,AKIL M,BILIK M,AYDIN M,POLAT N,YILDIZ A,Yüksel M,ÇİFTÇİ L,ÖZAYDOĞDU N,özbek m,alan s,TOPRAK N The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI. . 2016; 604 - 613.
IEEE ACET H,ERTAŞ F,AKIL M,BILIK M,AYDIN M,POLAT N,YILDIZ A,Yüksel M,ÇİFTÇİ L,ÖZAYDOĞDU N,özbek m,alan s,TOPRAK N "The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI." , ss.604 - 613, 2016.
ISNAD ACET, Halit vd. "The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI". (2016), 604-613.
APA ACET H, ERTAŞ F, AKIL M, BILIK M, AYDIN M, POLAT N, YILDIZ A, Yüksel M, ÇİFTÇİ L, ÖZAYDOĞDU N, özbek m, alan s, TOPRAK N (2016). The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI. Turkish Journal of Medical Sciences, 46(3), 604 - 613.
Chicago ACET Halit,ERTAŞ Faruk,AKIL Mehmet Ata,BILIK MEHMET ZIHNI,AYDIN MESUT,POLAT Nihat,YILDIZ Abdulkadir,Yüksel Murat,ÇİFTÇİ Leyla,ÖZAYDOĞDU Necdet,özbek mehmet,alan sait,TOPRAK Nizamettin The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI. Turkish Journal of Medical Sciences 46, no.3 (2016): 604 - 613.
MLA ACET Halit,ERTAŞ Faruk,AKIL Mehmet Ata,BILIK MEHMET ZIHNI,AYDIN MESUT,POLAT Nihat,YILDIZ Abdulkadir,Yüksel Murat,ÇİFTÇİ Leyla,ÖZAYDOĞDU Necdet,özbek mehmet,alan sait,TOPRAK Nizamettin The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI. Turkish Journal of Medical Sciences, vol.46, no.3, 2016, ss.604 - 613.
AMA ACET H,ERTAŞ F,AKIL M,BILIK M,AYDIN M,POLAT N,YILDIZ A,Yüksel M,ÇİFTÇİ L,ÖZAYDOĞDU N,özbek m,alan s,TOPRAK N The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI. Turkish Journal of Medical Sciences. 2016; 46(3): 604 - 613.
Vancouver ACET H,ERTAŞ F,AKIL M,BILIK M,AYDIN M,POLAT N,YILDIZ A,Yüksel M,ÇİFTÇİ L,ÖZAYDOĞDU N,özbek m,alan s,TOPRAK N The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI. Turkish Journal of Medical Sciences. 2016; 46(3): 604 - 613.
IEEE ACET H,ERTAŞ F,AKIL M,BILIK M,AYDIN M,POLAT N,YILDIZ A,Yüksel M,ÇİFTÇİ L,ÖZAYDOĞDU N,özbek m,alan s,TOPRAK N "The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI." Turkish Journal of Medical Sciences, 46, ss.604 - 613, 2016.
ISNAD ACET, Halit vd. "The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI". Turkish Journal of Medical Sciences 46/3 (2016), 604-613.